Navigation Links
Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
Date:6/16/2008

Results presented at the 90th annual Endocrine Society meeting show significant improvements among women affected by moderate to severe vaginal

dryness and painful intercourse

ANN ARBOR, Mich, June 16 /PRNewswire/ -- QuatRx Pharmaceuticals today announced detailed primary endpoint results from a pivotal Phase 3 clinical trial of Ophena(TM) (ospemifene tablets) to treat postmenopausal women with symptoms of vulvovaginal atrophy, a common condition associated with menopause. The study successfully met all four co-primary endpoints. Women treated with Ophena(TM) at the 60 mg dose showed statistically significant improvements in vaginal dryness and dyspareunia (painful intercourse), as well as statistically significant improvement in the proportion of parabasal and superficial cells in the epithelium of vaginal walls and a decline in vaginal pH levels. Results of this Phase 3 clinical trial were presented today in a poster presentation at the 90th annual Endocrine Society meeting in San Francisco.

The decline in estrogen levels in women after menopause is associated with an increase in vaginal pH levels as well as a thinning of the vaginal wall, resulting in bothersome symptoms such as vaginal dryness and painful intercourse. In the Phase 3 Ophena(TM) clinical study, women were asked to identify their most bothersome symptom of vaginal atrophy. The co-primary endpoints were defined as the change from baseline to week 12 in the percentage of parabasal cells in the vaginal maturation index, the percentage of superficial cells in the vaginal maturation index, vaginal pH, and improvements in the most bothersome moderate to severe vulvovaginal atrophy symptom.

"Vaginal atrophy symptoms in postmenopausal women are usually progressive and, unlike hot flashes, do not resolve spontaneously. They can have a significant impact on a woman's quality of life. These Phase 3 clinical study results indicate that this new oral tablet ha
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4

Related medicine technology :

1. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
2. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
3. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
4. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
5. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
6. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
9. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
10. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
11. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced ... dividend payment of $1.67 per share to all stockholders ... With this payment, distributions to stockholders for the ... In January 2010, the Company will make a ... 2009 cash distributions and the allocation between dividend income ...
(Date:12/15/2009)... KV Pharmaceutical Company ( KVa/KVb) today announced that ... notice (the "Notice") executed by the Marc S. Hermelin ... requesting that the Board of Directors of the Company ... by written consent relating to the proposed appointment of ... from Ronald J. Kanterman,s departure (the "Director Appointment"). ,, ...
(Date:12/15/2009)... Inc. and Alzheimer,s Weekly today announced the winners of ... designed to help five seniors in their fight to ... five winners will receive a $2,500 Dakim BrainFitness System, ... their brain health and the most widely adopted product ... country. ,, The contest, held to coincide ...
Breaking Medicine Technology:PDL BioPharma Completes December 15 Special Dividend Payment 2KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 2KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 3KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 4KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 5KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 6KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 75 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 25 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 3BCBSGA Announces Decision to Cover H1N1 Vaccine Administration 53494 1BCBSGA Announces Decision to Cover H1N1 Vaccine Administration 53494 2Anti growth factor drugs raise hope and concern for treatment of childrens eye diseases 53491 1Anti growth factor drugs raise hope and concern for treatment of childrens eye diseases 53491 2DNA computation gets logical at the Weizmann Institute of Science 9457 1DNA computation gets logical at the Weizmann Institute of Science 9457 2
(Date:12/15/2009)... SUMMARY: The U.S. Senate today rejected ... Care Act that would have helped make prescription ... and legal importation of lower priced drugs from ... sponsored by Senators Dorgan, Snowe, McCain, Grassley and ... bring down the skyrocketing costs of prescription drugs. ...
(Date:12/15/2009)... and Health Bureau has invited expressions of interest (EOI) ... hospitals at four sites in the Hong Kong Special ... 31, 2010. ,, At a press conference, the ... the promotion of private hospital development was one of ... Kong government policy announced by Chief Executive Donald Tsang ...
(Date:12/15/2009)... donated to the Lupus Foundation of America and the ... 15 Julian Lennon, son of the legendary ... new digital single, "LUCY," to raise funds for research ... 2010, 100 percent of the proceeds from downloading "LUCY" ... of America (LFA), and the Saint Thomas, Lupus Trust ...
(Date:12/15/2009)... reproductive age were evaluated, Italian study found , , TUESDAY, ... born with cystic fibrosis decreases when screening for potential ... new study finds. , CF neonatal screening has been ... years. Since the 1990s, the area has seen a ... with CF. , Two different CF carrier detection methods ...
(Date:12/15/2009)... needed for protection, CDC says, , , TUESDAY, Dec. 15 ... swine flu vaccine have been recalled by manufacturer Sanofi ... health officials said Tuesday. , According to the U.S. ... testing of the vaccine for children aged 6 months ... lower than required potency levels. "This means that doses ...
Breaking Medicine News(10 mins):Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 2Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 3Health News:Hong Kong Government Invites Expressions of Interest in Development of Private Hospitals 2Health News:Julian Lennon and James Scott Cook Release New Charity Single 'LUCY' to Raise Awareness and Funds for Lupus Research 2Health News:Wider Adult Screening May Mean Fewer Children With Cystic Fibrosis 2Health News:Large Recall of Children's Swine Flu Vaccine 2
... smoke have to drink more to feel drunk than ... to their brains, livers and hearts, a new study suggests. ... in rats, which are considered a good model for humans.Since ... drinking more alcohol to get an expected level of intoxication, ...
... shows that probiotics – bacteria like lactobacillus, often added ... infections.The latest study in the field shows children fed ... and require less antibiotic treatments. ,Probiotics are live ... promote healing by changing the balance of healthy and ...
... and upper airway inflammation have been found by researchers.Ulcerative ... inflammatory bowel disease (IBD) - involves inflammation of the ... now revealed a hitherto unexpected complication of IBD.// ... airway inflammation. One involved the larynx - or voice ...
... era where one fights battle towards eternity and hence ... indicators preclude the existance of newer solutions to fight ... on going research , Dr. Simona Giampaoli, from the ... MATISS Project have come out with a view that ...
... do with your genes, and everything to do with your upbringing ... extroverted are believed to be at least partly genetically determined - ... ,The team asked 71 pairs of identical twins and 56 ... five cartoons on a scale of 0 to 10.// A zero ...
... survivors report a good quality of life, despite facing physical ... assume that cancer must lead to a deterioration in your ... Hospital in Carolina carried out a survey on a group ... ,The women were asked a list of questions about the ...
Other Medicine News:
... inserter is designed for insertion of Alcon Acrylic, ... foldable lenses. The blades are taller and thinner, ... This feature prevents lens migration during loading and ... sweet spot on the folded lens optic. The ...
... (HARK) 599 is the first full-featured combination ... patient response on refraction results with visual ... positioned at either 90 or 180 to ... the HARK to the Humphrey Lens Analyzers ...
Neomycin and Polymyxin B Sulfates and Hydrocortisone otic suspension, USP is a sterile antibacterial and anti-inflammatory suspension for otic use....
Prednisolone Acetate ophthalmic suspension USP, 1% is an adrenocortical steroid product prepared as a sterile ophthalmic suspension....
Medicine Products: